It's the miracle drug known to curb appetite, stimulate weight loss and even help kick unhealthy addictions like smoking. But a new side effect has stumped doctors.

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Novo Nordisk stock wavered after its second-quarter earnings report early Wednesday as it vowed to cut costs amid ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

And it’s a problem with humankind in general. We do tend to crave quick fixes, often in pharmaceutical form. That’s why Henry ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.